QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Forecast, Price & News

$0.83
+0.02 (+2.47%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.81
$0.85
50-Day Range
$0.81
$1.47
52-Week Range
$0.80
$3.86
Volume
872,448 shs
Average Volume
1.13 million shs
Market Capitalization
$81.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.29
30 days | 90 days | 365 days | Advanced Chart
Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Adverum Biotechnologies logo

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADVM
Employees
188
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$3.22 per share

Profitability

Net Income
$-145.54 million
Pretax Margin
-1,940.53%

Debt

Price-To-Earnings

Miscellaneous

Free Float
86,523,000
Market Cap
$81.81 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/17/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

130th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

20th out of 210 stocks

Analyst Opinion: 3.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -













Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

Is Adverum Biotechnologies a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Adverum Biotechnologies
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.07.
View Adverum Biotechnologies' earnings history
.

What price target have analysts set for ADVM?

5 brokers have issued 12-month target prices for Adverum Biotechnologies' stock. Their forecasts range from $2.00 to $6.00. On average, they expect Adverum Biotechnologies' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 322.6% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adverum Biotechnologies' key executives?
Adverum Biotechnologies' management team includes the following people:
  • Dr. Laurent Fischer, Pres, CEO & Director (Age 58, Pay $922.92k) (LinkedIn Profile)
  • Dr. Rupert D'Souza M.B.A., Ph.D., Chief Financial Officer
  • Mr. Kishor Peter Soparkar J.D., Chief Operating Officer (Age 51)
  • Mr. Heikki Jouttijarvi, Sr. VP & Head of Technical Operations
  • Dr. Brigit Riley Ph.D., Chief Scientific Officer
  • Ms. Dena House, Sr. VP of HR, Organizational Devel. & Learning
  • Dr. Jim Wang Ph.D., Chief Regulatory Officer
  • Mr. Thomas Kochy, Sr. VP and Head of Global Product Strategy & Commercial
  • Mr. Michael Steel, Sr. VP of Quality
  • Mr. Anand Reddi, VP and Head of Corp. Strategy & External Affairs & Engagement
What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.41%), Vanguard Group Inc. (3.58%), State Street Corp (1.78%), JPMorgan Chase & Co. (1.71%), Assenagon Asset Management S.A. (1.01%) and Northern Trust Corp (0.77%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Julie Clark, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado, Peter Soparkar and Rupert D'souza.
View institutional ownership trends for Adverum Biotechnologies
.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Vanguard Group Inc., JPMorgan Chase & Co., Renaissance Technologies LLC, Goldman Sachs Group Inc., Simplex Trading LLC, GSA Capital Partners LLP, and Dimensional Fund Advisors LP. Company insiders that have sold Adverum Biotechnologies company stock in the last year include James Paul Scopa, and Julie Clark.
View insider buying and selling activity for Adverum Biotechnologies
or view top insider-selling stocks.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Invesco Ltd., Mirabella Financial Services LLP, and Marquette Asset Management LLC. Company insiders that have bought Adverum Biotechnologies stock in the last two years include Laurent Fischer, Patrick Machado, Peter Soparkar, and Rupert D'souza.
View insider buying and selling activity for Adverum Biotechnologies
or or view top insider-buying stocks.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $0.83.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies has a market capitalization of $81.81 million and generates $7.50 million in revenue each year. The biotechnology company earns $-145.54 million in net income (profit) each year or ($1.57) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 188 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at (650) 656-9323, via email at [email protected], or via fax at 650-329-8151.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.